6 results about "Ascorbyl glucoside" patented technology

The invention discloses a small nucleic acid freckle-removing essence, which is carefully matched with active ingredients such as siRNA, NARDOSTACHYS CHINENSIS extract, nicotinamide, ascorbyl glucoside, tranexamic acid and the like, not only can block the generation of melanin from the source, but also can promote the metabolism of skin, accelerate the metabolism of generated melanin, and achieve internal and external synergism, so that the freckle-removing essence has the effects of removing freckle, removing freckle and removing freckle. A good removing effect is achieved on freckles, chloasma and other color spots.

This invention relates to a method for synthesizing ascorbate glucoside via yeast lysate and its application, belonging to the field of cosmetic technology. The invention discloses a Bifida ferment lysate, which is a fermentation product lysate of *Bifidobacterium longum*, wherein the *Bifidobacterium longum* is at least one of *Bifidobacterium longum* HJ-005, *Bifidobacterium longum* subsp. *CGMCC* 1.2186, and *Bifidobacterium longum* subsp. *infant* CGMCC 1.15639; the nucleotide sequence of the 16S rRNA of *Bifidobacterium longum* HJ-005 is shown in SEQ ID NO: 1. This invention uses a specific fermentation product lysate of *Bifidobacterium longum* to catalyze the transglycosylation reaction of vitamin C, obtaining a reaction product containing AA2G, thereby increasing the yield of AA2G, significantly reducing the preparation cost of AA2G, and significantly inhibiting the production of melanin in zebrafish embryos, exhibiting a whitening effect. It can be used as a cosmetic raw material without purification.

The present invention relates to atopical detergent composition comprising ascorbyl glucoside and ascorbyl palmitate, a washing and transcutaneous absorption-promoting base comprising at least one non-ionic surfactant, at least one anionic surfactant, glycerol, in combination with suitable excipients and / or diluents.

This invention discloses a vitamin C smart delivery nanocomponent based on biomimetic imprinting technology and its anti-tumor application. The core of the nanocomponent is a SiO2 nanoparticle containing cytochrome C, and the surface is directionally imprinted with a vitamin C-specific imprinted cavity using ascorbyl glucoside (AA2G), a stable derivative of vitamin C, as a molecular imprinting template. The preparation steps include: SiO2 nanoparticles containing cytochrome C. 2 The synthesis, amino-functionalization, boric acid-functionalization, template immobilization, directional imprinting, secondary amino-functionalization, template removal, and DMMA modification of NPs-CC led to the construction of the nano-component vMIPDcc containing cytochrome C in its core and having a vitamin C-specific imprinted cavity on its surface. This nanocomponent exhibits high selectivity (IF=8.4) and reliable recognition ability for vitamin C. vMIPDcc achieved an in vivo inhibition rate of 60.2% against colon cancer, providing new ideas and options for the development of anti-colon cancer drugs.

The present invention relates to a cosmetic skin lightening composition comprising the combination of sclareolide, kojic acid and ascorbyl glucoside, wherein kojic acid is encapsulated within a targeted microcapsule or nanocapsule having a melanocortin 1 receptor (MC1R) agonist peptide bound to the surface. It was found that such combination of active substances provided synergistic kin-whitening effect. The present invention also relates to the cosmetic use of this composition for skin whitening, particularly, for the elimination or reduction of hyperpigmented marks of the skin, such as UV exposure related marks, post-scar marks, post-inflammation marks, melasma marks, lentigo marks or age-related marks.

The present application belongs to the technical field of genetic engineering and protein engineering, and relates to a site-directed mutant sucrose phosphorylase and application thereof. The site-directed mutant sucrose phosphorylase is obtained by making a point mutation in sucrose phosphorylase (BiSPase) with an amino acid sequence shown as SEQ ID NO. 1, and the mutation site of the point mutation is selected from the 141th and / or 197th. Preferably, the point mutation of the 141th is threonine mutated into cysteine; and the point mutation of the 197th is glycine mutated into cysteine. The catalytic efficiency of the sucrose phosphorylase variant enzyme provided by the present application is obviously improved, so that the yield of L-ascorbyl glucoside can be improved, the production cost is reduced, the problems of low receptor specificity and low enzyme activity of sucrose phosphorylase in the prior art are solved, and the sucrose phosphorylase has a wide industrial application prospect.